Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6796 to 6810 of 8915 results

  1. Gefurulimab for treating antibody-positive generalised myasthenia gravis [TSID12256]

    In development Reference number: GID-TA11848 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. KRAS mutation testing of tumours in adults with metastatic colorectal cancer (discontinued)

    Discontinued Reference number: GID-DT14

    Diagnostics guidance
    Discontinued

  3. Intensity modulated radiotherapy for prostate cancer [ID17]

    Discontinued Reference number: GID-TAG396

    Technology appraisal guidance
    Discontinued

  4. Hernia

    Discontinued Reference number: GID-CGWAVE0771

    NICE guideline
    Discontinued

  5. Diagnostic services

    Discontinued Reference number: GID-CGWAVE0773

    NICE guideline
    Discontinued

  6. Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer [TSID12021]

    In development Reference number: GID-TA11556 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [ID12203]

    In development Reference number: GID-TA11781 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Lower urinary tract symptoms in men, trans and non-binary people with a prostate: assessment and management (update)

    Discontinued Reference number: GID-NG10300

    NICE guideline
    Discontinued

  9. Non-bisphosphonates for treating osteoporosis [ID901]

    Discontinued Reference number: GID-TA10072

    Technology appraisal guidance
    Discontinued

  10. Ganaxolone for adjunctive treatment of epilepsy associated with tuberous sclerosis complex with CDKL5 deficiency disorder [TSID12126]

    In development Reference number: GID-TA11697 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]

    In development Reference number: GID-TA11546 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]

    In development Reference number: GID-TA11092 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Violence and aggression: short-term management in mental health, health and community settings

    Discontinued Reference number: GID-NG10397

    NICE guideline
    Discontinued

  14. Ipatasertib with fulvestrant for treating oestrogen-receptor positive HER2-negative advanced breast cancer after CDK 4/6 and aromatase inhibitor treatment [ID12194]

    In development Reference number: GID-TA11771 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. The Assurance Nasal Alar SpO2 Sensor (discontinued)

    Discontinued Reference number: GID-MT510

    Medical technologies guidance
    Discontinued